Rocket Pharmaceuticals, Inc. (RCKT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.29-0.87%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Rocket Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	687,100
EPS	—	-0.404
Annual ending 2026-12-31
Revenue	—	1.11M
EPS	—	-0.13
Annual ending 2027-12-31
Revenue	—	11.27M
EPS	—	-1.364

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash to fund operations into Q2 2028	A primary condition in Rocket Pharmaceuticals, Inc.'s published investment case. The stated target is Cash and investments sufficient to fund operations through 2028-Q2.	Improving	Cash and investments fall below levels needed to fund operations into 2028-Q2	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Cash, cash equivalents and investments were $322.6 million in 2026-Q1 and $283.7 million in 2026-Q2, with management consistently expecting these resources to fund operations into Q2 2028. The trajectory is delivering as cash runway guidance has been maintained despite some cash decline. Delivery assessment Oct 24, 2026
Manage operating losses and cash burn	A primary condition in Rocket Pharmaceuticals, Inc.'s published investment case. The stated target is Operating losses near -$48.5 million per quarter.	Intact	Operating losses worsen significantly beyond -$48.5 million per quarter	Operating income: $-46.922M FY2026-Q2; GAAP. Published target: Operating losses near -$48.5 million per quarter. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 10, 2026-46,922,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 6ec1fe52-6888-482d-9924-cf8f3f67da38. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Complete sale of Rare Pediatric Disease Priority Review Voucher	Rocket raised $180M selling a priority review voucher.	Intact	PRV sale not completed or proceeds not received by 2026-Q2	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The sale of the Rare Pediatric Disease Priority Review Voucher was completed in 2026-Q2 for $180 million, providing significant non-dilutive capital. Management has delivered on this priority with the transaction closed and proceeds reflected in cash balances. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.36

$-1.18 → $-1.36 · observed estimates

FY2027 revenue$0.01B

$0.02B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.18	$19,799,670	5 / 12
2026-07-25	$-1.18	$19,799,670	5 / 12
2026-07-26	$-1.18	$19,799,670	5 / 12
2026-07-27	$-1.18	$19,799,670	5 / 12
2026-07-28	$-1.18	$19,799,670	5 / 12
2026-07-29	$-1.18	$19,799,670	5 / 12
2026-07-30	$-1.27	$19,784,154	7 / 9
2026-07-31	$-1.27	$19,784,154	7 / 9
2026-08-01	$-1.27	$19,784,154	7 / 9
2026-08-02	$-1.18	$19,799,670	5 / 12
2026-08-03	$-1.18	$19,799,670	5 / 12
2026-08-04	$-1.27	$19,784,154	7 / 9
2026-08-05	$-1.27	$19,784,154	7 / 9
2026-08-06	$-1.18	$19,799,670	5 / 12
2026-08-07	$-1.27	$19,784,154	7 / 9
2026-08-08	$-1.18	$19,799,670	5 / 12
2026-08-09	$-1.18	$19,799,670	5 / 12
2026-08-10	$-1.18	$19,799,670	5 / 12
2026-08-12	$-1.27	$10,755,330	6 / 10
2026-08-13	$-1.27	$19,784,154	7 / 9
2026-08-14	$-1.27	$19,784,154	7 / 9
2026-08-15	$-1.27	$19,784,154	7 / 8
2026-08-16	$-1.27	$19,784,154	7 / 8
2026-08-17	$-1.27	$19,784,154	7 / 8
2026-08-18	$-1.27	$19,784,154	7 / 9
2026-08-19	$-1.27	$19,784,154	7 / 9
2026-08-20	$-1.31	$10,660,855	7 / 9
2026-08-21	$-1.31	$10,660,855	7 / 9
2026-08-22	$-1.31	$10,660,855	7 / 9
2026-08-23	$-1.31	$10,660,855	7 / 9
2026-08-24	$-1.31	$10,660,855	7 / 9
2026-08-25	$-1.31	$10,660,855	7 / 9
2026-08-26	$-1.31	$10,660,855	7 / 9
2026-08-27	$-1.31	$10,660,855	7 / 9
2026-08-28	$-1.31	$10,660,855	7 / 9
2026-08-29	$-1.31	$10,660,855	7 / 9
2026-08-30	$-1.31	$10,660,855	7 / 9
2026-08-31	$-1.31	$10,660,855	7 / 9
2026-09-01	$-1.31	$10,660,855	7 / 9
2026-09-02	$-1.33	$11,272,450	7 / 9
2026-09-03	$-1.33	$11,272,450	7 / 9
2026-09-04	$-1.33	$11,272,450	7 / 9
2026-09-05	$-1.33	$11,272,450	7 / 9
2026-09-06	$-1.33	$11,272,450	7 / 9
2026-09-07	$-1.33	$11,272,450	7 / 9
2026-09-08	$-1.33	$11,272,450	7 / 9
2026-09-09	$-1.33	$11,272,450	7 / 9
2026-09-10	$-1.33	$11,272,450	7 / 9
2026-09-11	$-1.33	$11,272,450	7 / 9
2026-09-12	$-1.33	$11,272,450	7 / 9
2026-09-13	$-1.33	$11,272,450	7 / 9
2026-09-14	$-1.33	$11,272,450	7 / 9
2026-09-15	$-1.33	$11,272,450	7 / 9
2026-09-16	$-1.33	$11,272,450	7 / 9
2026-09-17	$-1.33	$11,272,450	7 / 9
2026-09-18	$-1.33	$11,272,450	7 / 9
2026-09-19	$-1.33	$11,272,450	7 / 9
2026-09-20	$-1.33	$11,272,450	7 / 9
2026-09-21	$-1.33	$11,272,450	7 / 9
2026-09-22	$-1.33	$11,272,450	7 / 9
2026-09-23	$-1.33	$11,272,450	7 / 9
2026-09-24	$-1.33	$11,272,450	7 / 9
2026-09-25	$-1.36	$11,272,450	7 / 9
2026-09-26	$-1.36	$11,272,450	7 / 9
2026-09-27	$-1.36	$11,272,450	7 / 9
2026-09-28	$-1.36	$11,272,450	7 / 9
2026-09-29	$-1.36	$11,272,450	7 / 9
2026-09-30	$-1.36	$11,272,450	7 / 9
2026-10-01	$-1.36	$11,272,450	7 / 9
2026-10-02	$-1.36	$11,272,450	7 / 9
2026-10-03	$-1.36	$11,272,450	7 / 9
2026-10-04	$-1.36	$11,272,450	7 / 9
2026-10-05	$-1.36	$11,272,450	7 / 9
2026-10-06	$-1.36	$11,272,450	7 / 9
2026-10-07	$-1.36	$11,272,450	7 / 9
2026-10-08	$-1.36	$11,272,450	7 / 9
2026-10-09	$-1.36	$11,272,450	7 / 9
2026-10-10	$-1.36	$11,272,450	7 / 9
2026-10-11	$-1.36	$11,272,450	7 / 9
2026-10-12	$-1.36	$11,272,450	7 / 9
2026-10-13	$-1.36	$11,272,450	7 / 9
2026-10-14	$-1.36	$11,272,450	7 / 9
2026-10-15	$-1.36	$11,272,450	7 / 9
2026-10-16	$-1.36	$11,272,450	7 / 9
2026-10-17	$-1.36	$11,272,450	7 / 9
2026-10-18	$-1.36	$11,272,450	7 / 9
2026-10-19	$-1.36	$11,272,450	7 / 9
2026-10-20	$-1.36	$11,272,450	7 / 9
2026-10-21	$-1.36	$11,272,450	7 / 9
2026-10-22	$-1.36	$11,272,450	7 / 9
2026-10-23	$-1.36	$11,272,450	7 / 9
2026-10-24	$-1.36	$11,272,450	7 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	6	2
2026-06-01	6	6	2
2026-07-01	6	6	2
2026-08-01	6	6	2
2026-09-01	7	6	2
2026-10-01	7	6	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 6 Hold · 2 Sell / Strong Sell

1 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Goldman SachsOct 8

$4.00New observation · no comparable prior

JefferiesOct 7

$2.95New observation · no comparable prior

$0$2.20$4.40

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash to fund operations into Q2 2028Direct metric needs a verified mapping
Manage operating losses and cash burnOperating income: $-46.922M
Complete sale of Rare Pediatric Disease Priority Review VoucherDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-58.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Rocket Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech, not an established earnings compounder. The long-term thesis is on watch, with management showing progress on trial work and funding priorities but volatile execution and elevated risk.

What's priced into Rocket Pharmaceuticals, Inc.

The evidence provides no valuation multiple or clear measure of what the market expects, so whether RCKT is cheap or expensive versus peers cannot be assessed. The priced-in fragility signal is low, but that does not establish that expectations are modest.

What the fundamentals likely do

Near term, the risk of an earnings miss is elevated after a recent miss, while losses mean there is no established earnings base. Management has maintained its expectation that available resources fund operations into the second quarter of 2028, completed the voucher sale, and resumed dosing in the pivotal RP-A501 trial. Cash declined between the first and second quarters of 2026, and the next earnings report and clinical progress remain important tests.

What Rocket Pharmaceuticals, Inc. hinges on

The multi-year view depends on continued progress in the RP-A501 trial and whether the cash runway remains consistent with management’s stated plan. A guidance cut or further weakening in jobs data would add near-term pressure, while strong results and guidance from healthcare bellwethers could support sector momentum.